MannKind Corporation (MNKD) |
4.11 -0.07 (-1.67%) 04-22 16:00 |
Open: | 4.23 |
High: | 4.26 |
Low: | 4.105 |
Volume: | 1,670,377 |
Market Cap: | 1,111(M) |
PE Ratio: | -102.75 |
Exchange: | NASDAQ Global Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 5.11 |
Resistance 1: | 4.67 |
Pivot price: | 4.25 |
Support 1: | 3.97 |
Support 2: | 3.30 |
52w High: | 5.75 |
52w Low: | 3.17 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
EPS | -0.040 |
Book Value | -0.910 |
PEG Ratio | 0.88 |
Gross Profit | 0.000 |
Profit Margin (%) | -6.00 |
Operating Margin (%) | 18.19 |
Return on Assets (ttm) | 1.7 |
Return on Equity (ttm) | 0.0 |
Thu, 18 Apr 2024
Bearish: Analysts Just Cut Their MannKind Corporation (NASDAQ:MNKD) Revenue and EPS estimates - Yahoo Movies UK
Tue, 26 Mar 2024
MannKind Corp Announces CFO Transition and New Compensation Plan - TipRanks.com - TipRanks
Mon, 11 Mar 2024
What's Going On With MannKind Stock? - MannKind (NASDAQ:MNKD) - Benzinga
Sun, 03 Mar 2024
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year - Simply Wall St
Sun, 03 Mar 2024
Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts - Yahoo Finance
Sat, 02 Mar 2024
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |